There is positive news from two COVID-19 vaccine candidates considered frontrunners, from Moderna in the US and Oxford in the United Kingdom.
But experts cautioned that both represent only early, though useful, steps on a long road rather than definitive proof these vaccines will work.eight humans and that it stimulated an immune response"There were just eight people in it, so it's a bit of a leap of faith from that to imagining it will protect 7 billion people. But at least it went well, so you have to be encouraged by that," said Dr.
It’s presumed that any vaccine created for COVID-19 will require two doses spaced a month or two apart for full protection against the virus. The vaccine, called ChAdOx1, also appears to have prevented pneumonia and lung inflammatory disease when the animals were exposed to SARS-CoV-2.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Stocks rebound as positive Moderna vaccine trial boosts optimism for economic recoveryStocks bounced back Monday on optimism the U.S. economy may start to recover from the coronavirus pandemic after drugmaker Moderna released promising early results for a vaccine.
Weiterlesen »
Coronavirus live updates: 'Positive' vaccine data lifts Moderna stock; Spain's GDP could fall more than 9.5%Covid-19 has now infected more than 4.7 million people around the world as of Monday, killing at least 315,496 people.
Weiterlesen »
Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidateShares of Moderna Inc. jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said. There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25" micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna's vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus. The preclinical company said earlier this month that the Phase 2 trial will begin "shortly," and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna's stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%.
Weiterlesen »
Stocks making the biggest moves midday: Moderna, Delta, Bank of America, Best Buy, Disney & moreModerna shares spike on 'positive data' from its coronavirus vaccine trial. Netflix shares slip as investors rotate out of 'stay-at-home' stocks.
Weiterlesen »
Limited data on Moderna's coronavirus vaccine shows early promiseThe data is from eight people who took part in a safety trial that kicked off in March as the global pandemic caused by the novel coronavirus was spreading.
Weiterlesen »
Moderna will spike another 25% from current levels after encouraging progress on coronavirus vaccine, Goldman says | Markets InsiderGoldman Sachs lifted its price target for Moderna stock to $105 from $63 on Monday after first trials for its coronavirus drug showed 'encouragi...
Weiterlesen »